CARD11
CARD11 (Caspase recruitment domain-containing protein 11) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Hepatocellular carcinoma, Skin cancer and 5 more.
Overview
Adapter protein that plays a key role in adaptive immune response by transducing the activation of NF-kappa-B downstream of T-cell receptor (TCR) and B-cell receptor (BCR) engagement. Transduces signals downstream TCR or BCR activation via the formation of a multiprotein complex together with BCL10 and MALT1 that induces NF-kappa-B and MAP kinase p38 (MAPK11, MAPK12, MAPK13 and/or MAPK14) pathways. Upon activation in response to TCR or BCR triggering, CARD11 homooligomerises to form a nucleating helical template that recruits BCL10 via CARD-CARD interaction, thereby promoting polymerisation of BCL10 and subsequent recruitment of MALT1: this leads to I-kappa-B kinase (IKK) phosphorylation and degradation, and release of NF-kappa-B proteins for nuclear translocation.
CIViC holds 2 clinical evidence items and 0 assertions across 1 variant. Open Targets scores its association with cancer at 0.68 (direct and indirect evidence; datatypes literature 0.84, animal model 0.54, genetic association 0.00, somatic mutation 0.87). IntOGen calls it a driver in 11 cohorts (9 activating, 2 loss-of-function), covering Burkitt Lymphoma, Colorectal Adenocarcinoma, Diffuse Large B-Cell Lymphoma, NOS, Hepatocellular Carcinoma, Malignant Lymphoma, Non-Hodgkin Lymphoma and others.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · CARD11 (Caspase recruitment domain-containing protein 11) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Hepatocellular carcinoma, Skin cancer and 5 more.
- 1 · What it is
CARD11 (Caspase recruitment domain-containing protein 11) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Hepatocellular carcinoma, Skin cancer and 5 more.
- 2 · What goes wrong in cancer
Adapter protein that plays a key role in adaptive immune response by transducing the activation of NF-kappa-B downstream of T-cell receptor (TCR) and B-cell receptor (BCR) engagement.
- 3 · How drugs use it
No product in this corpus aims at CARD11 yet. Drugs fit a pocket that exists only in one shape of the mutant protein and hold it there, off.
External identifiers
Sources: HGNC HGNC:16393 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q9BXL7 (protein name, function text, keywords and locations (REST API)); CIViC gene CARD11 (2 evidence items, 0 assertions, 1 variants; diseases: Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma (GraphQL API, CC0)); Open Targets ENSG00000198286 (association with cancer (MONDO_0004992) 0.68; per-cancer scores at or above 0.5: colorectal cancer 0.55, gastric cancer 0.51, melanoma 0.54, diffuse large B-cell lymphoma 0.63, non-Hodgkin lymphoma 0.70, skin cancer 0.58 (GraphQL API, CC0)); IntOGen CARD11 (driver in 11 cohorts (Act 9, LoF 2); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Biology
Adapter protein that plays a key role in adaptive immune response by transducing the activation of NF-kappa-B downstream of T-cell receptor (TCR) and B-cell receptor (BCR) engagement. Transduces signals downstream TCR or BCR activation via the formation of a multiprotein complex together with BCL10 and MALT1 that induces NF-kappa-B and MAP kinase p38 (MAPK11, MAPK12, MAPK13 and/or MAPK14) pathways. Upon activation in response to TCR or BCR triggering, CARD11 homooligomerises to form a nucleating helical template that recruits BCL10 via CARD-CARD interaction, thereby promoting polymerisation of BCL10 and subsequent recruitment of MALT1: this leads to I-kappa-B kinase (IKK) phosphorylation and degradation, and release of NF-kappa-B proteins for nuclear translocation. Its binding to DPP4 induces T-cell proliferation and NF-kappa-B activation in a T-cell receptor/CD3-dependent manner. Promotes linear ubiquitination of BCL10 by promoting the targeting of BCL10 to RNF31/HOIP. Stimulates the phosphorylation of BCL10. Location: Cytoplasm; Membrane raft (UniProt). Locus 7p22.2 (HGNC).
- Non-Hodgkin lymphoma: Open Targets association 0.70 with non-Hodgkin lymphoma (MONDO_0018908); IntOGen driver in 2 cohorts (MLYM, NHL)
- Hepatocellular carcinoma: IntOGen driver in 2 cohorts (HCC)
- Skin cancer: Open Targets association 0.58 with skin cancer (MONDO_0002898)
- Colorectal cancer: Open Targets association 0.55 with colorectal cancer (MONDO_0005575); IntOGen driver in 1 cohort (COADREAD)
- Ovarian cancer: IntOGen driver in 1 cohort (OVT)
- Leukaemia: Open Targets association 0.53 with leukaemia (MONDO_0005059)
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: IntOGen calls it an activating (Act) driver in 9 cohorts; IntOGen calls it a loss-of-function (LoF) driver in 2 cohorts; CIViC holds 2 clinical evidence items on its variants. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"CARD11" OR ABSTRACT:"CARD11" OR TITLE:"caspase recruitment domain family member 11" OR ABSTRACT:"caspase recruitment domain family member 11" OR TITLE:"Caspase recruitment domain-containing protein 11" OR ABSTRACT:"Caspase recruitment domain-containing protein 11" OR TITLE:"CARMA1" OR ABSTRACT:"CARMA1" OR TITLE:"BIMP3" OR ABSTRACT:"BIMP3") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about CARD11, not a curated reading list.
Similar pages
not linked directly; found by shared links- TargetIL7R
Shares Leukaemia (all types), Lung cancer (all types), Skin cancer (all types), Non-Hodgkin lymphoma (all types).
- TargetSYK
Shares B-cell receptor / BTK signalling (to NF-κB), Leukaemia (all types), Lung cancer (all types), Skin cancer (all types).
- TargetJAK3
Shares Leukaemia (all types), Lung cancer (all types), Skin cancer (all types), Non-Hodgkin lymphoma (all types).
- TargetBARD1
Shares Lung cancer (all types), Skin cancer (all types), CIViC, IntOGen.
- TargetFANCA
Shares Leukaemia (all types), Lung cancer (all types), Skin cancer (all types), CIViC.
- TargetPOLD1
Shares Leukaemia (all types), Lung cancer (all types), Non-Hodgkin lymphoma (all types), CIViC.
- TargetPIK3R1
Shares Leukaemia (all types), Skin cancer (all types), CIViC, IntOGen.
- TargetPPP2R1A
Shares Lung cancer (all types), Skin cancer (all types), CIViC, IntOGen.